Fresh funding bridges f-star gap
Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas Venture, Aescap Venture, Novo Ventures and TVM Capital also participated in this round. The company says the fresh funding will be used to support drug discovery and development efforts. F-star is an antibody engineering company that develops improved therapeutic antibodies and antibody fragments based on its modular antibody technology, which allows the engineering of new antigen binding sites into constant and variable domains of antibodies. The company was founded in 2006 and has raised an overall total of EUR19m in funding. Its 20 employees are spread over its two research sites in Vienna and Cambridge (US).